Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06150898). This is a study registration, not published results. Lead sponsor: Jules Bordet Institute. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 112 participants (ESTIMATED). Conditions: Early-stage Breast Cancer, Estrogen-receptor-positive Breast Cancer. Interventions: PROCEDURE: Prospective data and sample collection; DRUG: Ketorolac 10 Mg Oral Tablet; DRUG: Pregabalin 75mg; DRUG: Omeprazole 20mg Capsule. Primary outcome measures: To detect a reduced increase in systemic inflammation (from baseline to up to 24 hours after surgery) using peri-operative ketorolac , Up to 24 hours after surgery; To detect a reduced increase in systemic neurotransmitters (from baseline to up to 24 hours after surgery) using peri-operative pregabalin , Up to 24 hours after surgery; Change in biomarkers of metastasis at surgery from baseline , At surgery; Change in tumoral immune cells recruitment at surgery from baseline , At surgery; Change in tumoral neurogenesis at surgery from baseline , At surgery; Change in tumoral neurotransmitters level at surgery from baseline , At surgery; Change in Peripheral Blood Mononuclear Cells at surgery from baseline , At surgery; Change in systemic neuro-inflammatory mediators at surgery from baseline , At surgery; Change in systemic neurotransmitters at surgery from baseline , At surgery. Brief summary: Out of all proportion to its short duration, the perioperative period is critical in determining the long-term outcome of cancer. To contribute to a better understanding of the neural and inflammatory mechanisms underlying this issue, we aim to implement a novel intervention based on the preoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) with or without an anti-epileptic drug. Our goal is to understand and transform the perioperative window from being a facilitator of metastatic progression to arresting and/or eliminating residual disease using repurposing drugs